Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Leite, S. Reis, N. Viana, D. Morais, C. Moura, I. Silva, J. Pontes, B. Katz, M. Srougi (2015)
Controlling RECK miR21 Promotes Tumor Cell Invasion and Is Related to Biochemical Recurrence in Prostate CancerJournal of Cancer, 6
Pallavi Patil, C. Magi-Galluzzi (2015)
MicroRNA in prostate cancer: Practical aspects.Histology and histopathology, 30 12
U. Lo, Di Yang, J. Hsieh (2013)
The role of microRNAs in prostate cancer progressionTranslational Andrology and Urology, 2
Elizabeth Wei, J. Hsieh (2015)
A river model to map convergent cancer evolution and guide therapy in RCCNature Reviews Urology, 12
S. Melo, R. Kalluri (2012)
Molecular Pathways: MicroRNAs as Cancer TherapeuticsClinical Cancer Research, 18
F. Takeshita, Lubna Patrawala, M. Osaki, Ryou-u Takahashi, Yusuke Yamamoto, N. Kosaka, Masaki Kawamata, K. Kelnar, A. Bader, D. Brown, T. Ochiya (2010)
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.Molecular therapy : the journal of the American Society of Gene Therapy, 18 1
K. Uchino, T. Ochiya, F. Takeshita (2013)
RNAi therapeutics and applications of microRNAs in cancer treatment.Japanese journal of clinical oncology, 43 6
S. Oudard, Y. Vano (2015)
The role of rechallenge with targeted therapies in metastatic renal-cell carcinomaCurrent Opinion in Urology, 25
D. Penson, A. Armstrong, R. Concepcion, N. Agarwal, C. Olsson, L. Karsh, C. Dunshee, Fong Wang, Kenneth Wu, A. Krivoshik, D. Phung, C. Higano (2016)
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 18
A. Schaefer, C. Stephan, J. Busch, G. Yousef, K. Jung (2010)
Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumorsNature Reviews Urology, 7
Zhuo Fang, N. Rajewsky (2011)
The Impact of miRNA Target Sites in Coding Sequences and in 3′UTRsPLoS ONE, 6
N. Mercatelli, V. Coppola, D. Bonci, F. Miele, Arianna Costantini, Marco Guadagnoli, E. Bonanno, G. Muto, G. Frajese, R. Maria, L. Spagnoli, M. Farace, S. Ciafrè (2008)
The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in MicePLoS ONE, 3
K. Leite, A. Tomiyama, S. Reis, Juliana Sousa-Canavez, A. Sañudo, L. Câmara-Lopes, M. Srougi (2013)
MicroRNA expression profiles in the progression of prostate cancer--from high-grade prostate intraepithelial neoplasia to metastasis.Urologic oncology, 31 6
Martin Hart, S. Wach, E. Nolte, Jaroslaw Szczyrba, R. Menon, H. Taubert, A. Hartmann, R. Stoehr, W. Wieland, F. Grässer, B. Wullich (2013)
The proto‐oncogene ERG is a target of microRNA miR‐145 in prostate cancerThe FEBS Journal, 280
S. Wach, E. Nolte, Jaroslaw Szczyrba, R. Stöhr, A. Hartmann, T. Ørntoft, L. Dyrskjøt, E. Eltze, W. Wieland, B. Keck, A. Ekici, F. Grässer, B. Wullich (2012)
MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screeningInternational Journal of Cancer, 130
M. Ozen, M. Ozen, C. Creighton, M. Ozdemir, M. Ittmann (2008)
Widespread deregulation of microRNA expression in human prostate cancerOncogene, 27
T. Farazi, Jessica Spitzer, Pavel Morozov, T. Tuschl (2011)
miRNAs in human cancerThe Journal of Pathology, 223
J. Bissler, F. McCormack, L. Young, J. Elwing, G. Chuck, J. Leonard, V. Schmithorst, T. Laor, A. Brody, J. Bean, S. Salisbury, D. Franz (2008)
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.The New England journal of medicine, 358 2
A. Drusco, C. Croce (2017)
MicroRNAs and Cancer: A Long Story for Short RNAs.Advances in cancer research, 135
M. Avgeris, Konstantinos Stravodimos, E. Fragoulis, A. Scorilas (2013)
The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patientsBritish Journal of Cancer, 108
E. Tiacci, Jae Park, L. Carolis, S. Chung, A. Broccoli, Sasinya Scott, F. Zaja, S. Devlin, A. Pulsoni, Y. Chung, M. Cimminiello, Eunhee Kim, D. Rossi, R. Stone, G. Motta, A. Saven, M. Varettoni, J. Altman, A. Anastasia, M. Grever, A. Ambrosetti, K. Rai, V. Fraticelli, M. Lacouture, A. Carella, R. Levine, P. Leoni, A. Rambaldi, F. Falzetti, S. Ascani, M. Capponi, M. Martelli, Christopher Park, S. Pileri, N. Rosen, R. Foà, M. Berger, P. Zinzani, O. Abdel-Wahab, B. Falini, M. Tallman (2015)
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.The New England journal of medicine, 373 18
Laurence Klotz, D. Drachenberg, R. Singal, A. Aprikian, Y. Fradet, M. Kebabdjian, M. Zarenda, J. Chin (2014)
An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium StudyProstate Cancer and Prostatic Disease, 17
Marta García, R. Vélez, C. Romagosa, B. Majem, Núria Pedrola, M. Oliván, M. Rigau, M. Guiu, R. Gomis, J. Morote, J. Reventós, A. Doll (2014)
Cyclooxygenase‐2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude miceBJU International, 113
V. Kim, Jinju Han, M. Siomi (2009)
Biogenesis of small RNAs in animalsNature Reviews Molecular Cell Biology, 10
F. Takeshita, Y. Minakuchi, S. Nagahara, Kimi Honma, Hideo Sasaki, Kotaro Hirai, T. Teratani, Nachi Namatame, Yusuke Yamamoto, K. Hanai, Takashi Kato, A. Sano, T. Ochiya (2005)
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.Proceedings of the National Academy of Sciences of the United States of America, 102 34
K. Leite, Juliana Sousa-Canavez, S. Reis, A. Tomiyama, L. Câmara-Lopes, A. Sañudo, A. Antunes, M. Srougi (2011)
Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis.Urologic oncology, 29 3
Prostate cancer (PCa) is an incurable disease at the metastatic stage. Although there are different options for treatment, the results are limited. MicroRNAs (miRNAs) are a group of small, noncoding, regulatory RNAs with important roles in regulating gene expression. miR-145 is reported to be a key tumor suppressor miRNA (tsmiR) that controls important oncogenes, such as MYC and RAS. In this study, in vitro studies were performed to show the control of MYC and RAS by miR-145. Flow cytometry was used to analyze cell proliferation and apoptosis. The efficacy of miR-145 in treating metastatic PCa was tested in nude mice using a model of bone metastasis promoted by intraventricular injection of PC-3MLuc-C6 cells. Tumor growth was evaluated by an in vivo bioluminescence system. After the full establishment of metastases on day 21, six animals were treated with three intravenous doses of miR-145 (on days 21, 24 and 27), and six were injected with scramble miRNA as controls. Compared to the controls, tumor growth was significantly reduced in animals receiving miR-145, most importantly on day 7 after the third and last dose of miRNA. After discontinuing the treatment, tumor growth resumed, becoming similar to the group of non-treated animals. A decrease in MYC and RAS expression was observed in all cell lines after treatment with miR-145, although statistical significance was achieved only in experiments with LNCaP and PC3 cell lines, with a decrease in 56% (p = 0.012) and 31% (p = 0.013) of RAS expression, respectively. Our results suggest that miR-145 is a potential molecule to be tested for treatment of metastatic, castration-resistant PCa.
Apoptosis – Springer Journals
Published: Jun 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.